MRUS vs. ACAD, MLTX, BHC, MOR, TGTX, FOLD, ARWR, CORT, JANX, and IDYA
Should you be buying Merus stock or one of its competitors? The main competitors of Merus include ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), MorphoSys (MOR), TG Therapeutics (TGTX), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Corcept Therapeutics (CORT), Janux Therapeutics (JANX), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
Merus (NASDAQ:MRUS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
96.1% of Merus shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 4.6% of Merus shares are held by insiders. Comparatively, 27.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ACADIA Pharmaceuticals has higher revenue and earnings than Merus. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.
Merus currently has a consensus price target of $56.33, suggesting a potential upside of 22.86%. ACADIA Pharmaceuticals has a consensus price target of $28.94, suggesting a potential upside of 90.63%. Given ACADIA Pharmaceuticals' higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Merus.
In the previous week, ACADIA Pharmaceuticals had 33 more articles in the media than Merus. MarketBeat recorded 54 mentions for ACADIA Pharmaceuticals and 21 mentions for Merus. Merus' average media sentiment score of 0.48 beat ACADIA Pharmaceuticals' score of 0.09 indicating that Merus is being referred to more favorably in the media.
Merus has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
ACADIA Pharmaceuticals has a net margin of -0.21% compared to Merus' net margin of -390.36%. ACADIA Pharmaceuticals' return on equity of -0.41% beat Merus' return on equity.
ACADIA Pharmaceuticals received 552 more outperform votes than Merus when rated by MarketBeat users. Likewise, 72.96% of users gave ACADIA Pharmaceuticals an outperform vote while only 65.66% of users gave Merus an outperform vote.
Summary
ACADIA Pharmaceuticals beats Merus on 13 of the 18 factors compared between the two stocks.
Get Merus News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
